0.11
0.00%
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sernova Biotherapeutics
Its shares trade on Toronto Stock Exchange under the ticker SVA.TO. It has been listed since 15 April 1999.
Sernova Corp. is a clinical stage regenerative medicine company, which engages in the development and commercialization of the proprietary technologies, including Cell Pouch implantable device technologies and immune-protected therapeutic cells. The company is headquartered in London, Ontario. The firm is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology lead asset, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Apr 1999
- Website
- sernova.com ↗
Leadership
Pay as last reported
- Mr. Ross HaghighatChairman of the Board, since 2025
- Mr. Jonathan RigbyPresident, Chief Executive Officer, Executive Director, since 2024
- Mr. James ParsonsChief Financial Officer, Director, since 2012C$183,265
- Dr. Philip ToleikisChief Technology Officer, since 2009C$1.2m
- Mr. Frank ShannonVice President - Clinical Development and Regulatory AffairsC$463,257
- Dr. Modestus ObochiChief Business OfficerC$739,318
- Ms. Marylyn RigbyChief Communications Officer
- Dr. David PatersonDirector
- Dr. Daniel MahonyIndependent DirectorC$295,069
- Dr. Steven SanghaIndependent DirectorC$158,357
- Mr. Bertram von PlettenbergIndependent DirectorC$161,898
- Mr. David BurkeVice President, Investor Relations, since 2024
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sernova Biotherapeutics Inc develops Cell Pouch System for diabetes treatment in London, Ontario.
- The Cell Pouch System creates vascularized environments for therapeutic cells in regenerative medicine.
- Sernova focuses on functional cure for insulin-dependent diabetes using immune-protected cells.
Weaknesses
- Sernova Corp. is a clinical stage company with no commercial products yet.
- The Cell Pouch System requires further clinical trials for regulatory approval.
- Sernova operates in a highly competitive biotechnology sector.
Opportunities
- Sernova's Cell Pouch System targets the growing diabetes market in North America.
- The regenerative medicine sector shows potential for expansion in Health Care industry.
- Sernova can leverage partnerships for Cell Pouch System development.
Threats
- Regulatory hurdles may delay Cell Pouch System approval in Canada.
- Competition from established biotech firms in Health Care sector.
- Economic downturns could impact funding for clinical stage biotechnology companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.